Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

RCT reported improved progression-free in 192 Chinese patients treated with surufatinib vs placebo (9.2 vs 3.8 months; HR 0.33; 95% CI 0.22–0.50; p<0.0001). Most common grade 3 or worse adverse events were hypertension (36% vs 13%) and proteinuria (19% vs zero).

SPS commentary:

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor.


The phase III SANET-p RCT reported improved progression-free survival with surufatinib, vs placebo in advanced pancreatic neuroendocrine tumours (n=172; 10.9 vs 3.7 months; HR 0.49, 95% CI 0.32–0.76; p=0.0011). 


The Lancet Oncology

Resource links: